Aurion Biotech Appoints Donald Munoz as Chief Financial Officer — Neutral
NCNA Business Wire — February 10, 2025SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer — Neutral
IOVA GlobeNewsWire — February 10, 2025SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today.
CRBU STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
CRBU Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period").
Leading Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending Matthews International Shareholders Vote the GOLD Proxy Card "FOR" ALL of Barington Capital's Nominees: Ana Amicarella, Chan Galbato and James Mitarotonda — Neutral
MATW PRNewsWire — February 10, 2025Glass Lewis Finds Matthews Has "Persistently Deteriorated and Consistently Underperformed During Substantially All Measurement Periods, Including During the Fullness of Mr. Bartolacci's Tenure as CEO" Asserts Barington "Has Offered Investors a Reasonable, Credible and Incremental Slate of Candidates" and a "More Promising Roadmap" for the Company Recommends Shareholders Vote "WITHHOLD" on Matthews' Nominees Terry L.
Beamr CEO will Present a Keynote Speech at the ACM Mile-High-Video 2025 — Neutral
BMR GlobeNewsWire — February 10, 2025The Keynote Titled ״Is the future of video processing destined for GPU?״ Describes First Hand The Evolution of Video Encoding in the Past Decades Herzliya Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd.
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! — Neutral
RVNC Accesswire — February 10, 2025NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
PSNY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Polestar Automotive Holding UK PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
PSNY Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Polestar Automotive Holding UK PLC ("Polestar" or "the Company") (NASDAQ:PSNY) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Polestar securities between November 14, 2022 and January 16, 2025, both dates inclusive (the "Class Period").
KSPI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Joint Stock Company Kaspi.kz Investors Have Opportunity to Lead Class Action Lawsuit! — Neutral
KSPI Accesswire — February 10, 2025NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Joint Stock Company Kaspi.kz ("Kaspi.kz" or "the Company") (NASDAQ:KSPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kaspi.kz securities between January 19, 2024 and September 19, 2024, both dates inclusive (the "Class Period").
APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! — Neutral
APLT Accesswire — February 10, 2025NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period").
SHANGHAI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ECARX Holdings, Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced a significant upgrade to its ECARX AutoGPT in-vehicle AI large model application with the integration of the DeepSeek-R1 model, resulting in a faster, more secure, and more personalized user experience. This advancement expands AutoGPT's local processing capabilities and enhances its reasoning and decision-making abilities for automotive-specific application scenarios.
Tower Semiconductor Reports 2024 Fourth Quarter and Full Year Financial Results — Neutral
TSEM GlobeNewsWire — February 10, 2025MIGDAL HAEMEK, Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the fourth quarter of 2024 and for the year ended December 31, 2024.
FINAL REMINDER SUI DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Sun Communities, Inc. Investors to Participate in the Class Action Lawsuit — Neutral
SUI Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sun Communities, Inc. ("Sun Communities" or "the Company") (NYSE:SUI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sun Communities securities between February 28, 2019 and September 24, 2024, both dates inclusive (the "Class Period").
DMC Global Acknowledges Non-Binding Proposal from Steel Connect — Neutral
BOOM GlobeNewsWire — February 10, 2025BROOMFIELD, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- DMC Global Inc. (Nasdaq: BOOM) (“DMC” or the “Company”) today acknowledged receipt of a non-binding proposal from Steel Connect to acquire all of the outstanding shares of common stock of the Company, not already owned by Steel Connect, for $10.18 per share in cash (the “Proposal”).
With No Competing Offers, Beacon Roofing's Board Stalls and Misleads — Neutral
QXO GlobeNewsWire — February 10, 2025Beacon Insiders Recently Sold Shares Well Below Offer Price, Undermining Beacon's Case Against QXO QXO Calls on Beacon Roofing to Let Shareholders Decide on QXO's $124.25 All-Cash Offer GREENWICH, Conn., Feb. 10, 2025 (GLOBE NEWSWIRE) -- QXO, Inc. (NYSE: QXO) today released a letter to Beacon Roofing Supply, Inc. shareholders regarding its $124.25 per share all-cash offer, addressing misrepresentations in Beacon's recent 14D-9 filing.
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
PCRX Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update — Neutral
ROIV GlobeNewsWire — February 10, 2025BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in second half of calendar year 2026 IMVT-1402 development is rapidly progressing with six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) initiated Batoclimab …
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 — Neutral
BCRX GlobeNewsWire — February 10, 2025RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025.
Hain Celestial Reports Fiscal Second Quarter 2025 Financial Results — Neutral
HAIN GlobeNewsWire — February 10, 2025Strong Operating Cash Flow and Reduction in Debt; Positioned to Pivot to Growth in Back Half Exploring Strategic Options for Personal Care Category
Orion Group Holdings Awarded $211.7 Million in New Contracts — Neutral
ORN GlobeNewsWire — February 10, 2025HOUSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”, “Orion”), a leading specialty construction company, today announced new Marine and Concrete awards for a total value of approximately $211.7 million. These projects are expected to begin in 2025 with varying completion dates extending through 2026. These awards further reinforce Orion's position as a leader in specialized Marine and Concrete construction.
monday.com Announces AI Vision to Empower Businesses to Scale — Neutral
MNDY Business Wire — February 10, 2025NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--monday.com Ltd. (NASDAQ: MNDY) (“monday.com”), the multi-product platform that runs all core aspects of work, today announced its AI Vision, representing its key focus areas for 2025. Building on its robust platform, monday.com's strategy will focus on three pillars—AI Blocks, Product Power-ups, and the Digital Workforce—to accelerate its vision to democratize the power of software. monday.com's approach to AI aims to address the unique challenges b.